Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
BON Catalyst Timeline
Dated clinical, regulatory and corporate events for Bon Natural Life Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bon Natural Life Limited
Event history 50
Past FDA Catalysts and PDUFA Decisions
How BON actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BON program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in BON
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BON for Q3 2026. | ||||
Ownership Trends
BON Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How BON ranks across every disease it competes in
BON News
BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation
Bon Natural Life Limited announced the establishment of the BON Joint Lab with China Oat Group to advance biomanufacturing of natural ingredients. The lab will focus on AI-driven technologies and developing standards for oat-derived products. This collaboration aims to address supply challenges and enhance market potential for natural health products.
Read more →BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
Bon Natural Life Limited has announced a strategic partnership with Tigerbone Group to enhance collaboration in traditional Chinese medicine and life sciences. The agreement includes the formation of the 'BON Cooperation and Development Committee' to drive innovation and product development. This partnership aims to consolidate resources and leverage complementary strengths for global growth.
Read more →BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market
Bon Natural Life Limited has announced the successful development of a premium anti-aging bio-electronic facial mask using apple polyphenols and advanced AI-enabled technology. Initial internal evaluations show that the mask exceeds performance benchmarks for skin appearance and firmness. The company is moving towards third-party clinical testing and plans to optimize large-scale manufacturing. With the anti-aging market exceeding $100 billion, BON aims to position itself as a leader in this emerging segment.
Read more →BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing
Bon Natural Life Limited has launched the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing in collaboration with Chang'an Pilot. This facility aims to enhance the research and development of bio-manufactured natural ingredients for functional foods and personal care products. The initiative is expected to improve production efficiency and sustainability through innovative technologies.
Read more →Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing
Bon Natural Life Limited has partnered with Chang'an Pilot to launch a Joint Laboratory for Natural Ingredients and Bio-Manufacturing in Xi'an, China, as announced on February 17, 2026. This collaboration aims to enhance research and development of bio-manufactured natural ingredients for functional foods and personal care products. The laboratory will utilize fermentation-based biosynthesis and artificial intelligence to optimize production processes, providing a more sustainable alternative to traditional methods. The partnership is expected to advance BON's growth strategy and improve production efficiency.
Read more →BON Unveils Kombucha-Inspired Product, Inks $12 Million Strategic Sales Agreement with Qingshengyuan
Bon Natural Life Limited has launched a new kombucha-inspired beverage and entered a $12 million strategic sales agreement with Shaanxi Qingshengyuan Health Industry Co., Ltd. The partnership aims to distribute BON's tea-pigment products across Greater China over the next 24 months. This move aligns with the growing consumer interest in natural ingredients and functional beverages.
Read more →BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan
Bon Natural Life Limited has announced a cooperation agreement with Beijing Huahai Keyuan for the distribution of its second-generation tea pigment-based digestive health products in Greater China. The agreement, valued at US$26 million over 36 months, aims to leverage the growing demand for digestive wellness and blood-glucose management. BON's innovative tea pigments have shown significant improvements in health benefits, positioning the company for growth in the premium digestive health market.
Read more →BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of
BON Natural Life Limited released its condensed consolidated balance sheets for the period ending March 31, 2025. The company reported total assets of $71.58 million, reflecting a growth from $61.77 million at the end of the previous period. Notably, net income attributable to the company improved compared to the prior period. However, the company also faced a comprehensive loss, showcasing challenges in profitability despite asset growth.
Read more →BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products
Bon Natural Life Limited has announced a non-exclusive cooperation agreement worth $18 million with Beijing Huahai Keyuan Technology to distribute its innovative second-generation Apple Series health products in Greater China. This new product line boasts 80% higher bioactivity and aims to meet the growing demand in weight management and metabolic health. The company is optimistic about its market performance and potential revenue growth.
Read more →BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
Bon Natural Life Limited has announced the identification of natural polyphenolic compounds from tea that show promise in weight management through its AI-powered R&D platform. Preliminary tests indicate these compounds outperform existing weight-managing drugs. With the global obesity crisis driving market growth, BON aims to capture a significant share of the weight management therapeutics market.
Read more →BON Announces Reciept of Nasdaq Compliance Letter
Bon Natural Life Limited has announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2). The Nasdaq Hearings Panel confirmed this decision, and the compliance matter is now closed. The company will be subject to a one-year Discretionary Panel Monitor, ensuring ongoing compliance oversight.
Read more →BON Launches AI-Powered New Drug Research and Development
Bon Natural Life Limited has launched an AI-driven drug research and development business, leveraging its library of natural compounds, particularly from Traditional Chinese Medicine. This initiative aims to enhance the efficiency and success rate of drug discovery by identifying promising lead compounds. CEO Yongwei Hu expressed optimism about achieving breakthroughs in pharmaceutical research through this strategic evolution.
Read more →BON Announces $22 Million Distribution Agreement for Weight Loss Products with Beijing Huahai Keyuan Technology Co., Ltd
Bon Natural Life Limited has announced a $22 million distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. for its weight loss products. This non-exclusive agreement spans 36 months and allows Huahai Keyuan to distribute BON's innovative weight management line across China and Southeast Asia. The products are designed to facilitate weight management without requiring significant lifestyle changes.
Read more →BON Announces Nasdaq Compliance
Bon Natural Life Limited has announced that it has regained compliance with Nasdaq's continued listing requirements. The company received formal notice from the Nasdaq Hearings Panel confirming it met the Minimum Bid Price Requirement. BON will remain under a Discretionary Panel Monitor for one year to ensure ongoing compliance.
Read more →Bon Announces Breakthrough Order for $16 Million Gut-Health Products
Bon Natural Life Limited has announced a $16 million distribution agreement with Beijing Huahai Keyuan Technology to market its new prebiotic products in China. This partnership is expected to enhance Bon's presence in the growing gut health market. The innovative product series features a unique 'Prebiotic + Postbiotic' complex aimed at improving gut microbiota health.
Read more →Bon Natural Life Announces Distribution Agreement with Tianjin Merrill-Youli Trading Co., Ltd.
Bon Natural Life Limited has announced a non-exclusive distribution agreement with Tianjin Merrill-Youli Trading Co., Ltd. The agreement, valued at up to $18 million over 36 months, will see Merrill-Youli market and distribute Bon's Ambroxide and related fragrance compounds in the Asia-Pacific region. The partnership aims to strengthen Bon's position in the fragrance market, particularly in fabric applications, while also advancing the development of a biosynthetic alternative to Sclareol.
Read more →BON Announces Share Repurchase Program for up to US$1.0 Million
Bon Natural Life Limited has announced a share repurchase program allowing for the purchase of up to $1.0 million of its Class A ordinary shares. The program's execution will depend on various factors including market conditions and corporate liquidity. TradeUp Securities has been appointed as the exclusive agent for the repurchase. This initiative reflects the company's confidence in its financial stability.
Read more →BON Announces Launch of Tea Pigment Digestive Health Products and Cooperation Agreement Signed with Shanghai Risesun International Trade
Bon Natural Life Limited has announced a sales cooperation agreement with Shanghai Risesun International Trade to market its tea pigment health products in China. The agreement, valued at $24 million over 24 months, aims to tap into the growing demand for digestive wellness and blood glucose regulation. CEO Hu Yongwei emphasized the partnership's potential to accelerate revenue growth and expand BON's market presence.
Read more →BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement
Bon Natural Life Limited (BON) has announced the launch of its patented postbiotic hypoglycemic ingredient product series and an exclusive cooperation agreement with Beijing Huahai Keyuan. The agreement, valued at 32 million USD, aims to enhance BON's presence in the global blood sugar health market. The new ingredient is designed to effectively regulate blood sugar levels, offering safety and convenience for users.
Read more →Bon Natural Life Limited Announces Effectiveness of Reverse Stock Split
Bon Natural Life Limited announced a 1-for-25 reverse stock split effective May 19, 2025, to comply with Nasdaq's minimum bid price requirement. The split will not affect shareholders' percentage interests. The company also increased its authorized share capital and adjusted the conversion rate for Class B shares. This decision was approved by shareholders at an extraordinary general meeting.
Read more →